Extension Study of Herombopag for Pediatric Patients With Chronic Immune Thrombocytopenia
Status:
Not yet recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
The main purpose of this extended study is to enable subjects who are currently receiving the
PartB experimental drug in the HR-TPO-ITP-III-PED clinical trial .To continue receiving the
experimental drug after the completion of the clinical trial if they benefit from the
treatment at the end of the clinical trial.Until the study physician determines that the
subject has failed treatment or that the subject can no longer benefit from treatment or
extends the study treatment for 6 months.In addition, the secondary purpose of this extended
study was to observe the long-term efficacy and safety of tripodal in children and
adolescents.